Standout Papers

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors 2021 2026 2022 2024299
  1. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors (2021)
    Leigh Marcus, Lola A. Fashoyin‐Aje et al. Clinical Cancer Research

Immediate Impact

56 standout
Sub-graph 1 of 23

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives
2025 Standout
1 intermediate paper

Works of Lisa Rodríguez being referenced

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
2020
FDA's Approval of the First Biosimilar to Bevacizumab
2018

Author Peers

Author Last Decade Papers Cites
Lisa Rodríguez 573 297 127 274 19 984
Martha Donoghue 654 374 123 237 26 1.1k
Yihuan Xu 543 232 102 321 19 1.0k
Martin Wiesenfeld 621 205 64 273 33 971
Casey W. Williamson 364 201 108 296 30 894
Ho-Yeong Lim 342 301 142 295 31 850
Cécile Charpy 640 250 273 207 29 1.1k
Kotaro Kodama 366 228 292 223 10 873
H. C. Falkson 600 199 85 172 32 1.0k
Antonella Licchetta 482 128 107 208 22 815
Mónica Musteanu 541 142 63 392 31 930

All Works

Loading papers...

Rankless by CCL
2026